In short
Elafibranor is an investigational drug being studied in clinical trials for various liver conditions, including nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). These trials aim to evaluate the safety, efficacy, and pharmacokinetics of elafibranor in different patient populations. The studies range from early phase 1 trials in healthy volunteers to larger phase 3 trials in patients with liver diseases.
At a glance
- Drug Name
- Elafibranor (also known as GFT505, IPN60190)
- Main Conditions Studied
- Nonalcoholic steatohepatitis (NASH), Primary biliary cholangitis (PBC)
- Administration
- Oral tablet, typically 80 mg or 120 mg once daily
- Key Outcome Measures
- Liver enzyme levels (e.g. ALP), liver histology, fibrosis, cholesterol levels, pruritus, fatigue
- Trial Phases
- Phase 1 to Phase 3
- Study Populations
- Healthy volunteers, NASH patients, PBC patients, patients with hepatic or renal impairment
- Trial Durations
- Range from a few weeks to several years
- Safety Assessments
- Adverse events, lab tests, physical exams, ECGs, vital signs
What is Elafibranor?
Elafibranor, also known as GFT505 or IPN60190, is an experimental drug being developed to treat various liver diseases. It is taken as an oral tablet and is currently undergoing clinical trials to evaluate its safety and effectiveness.
What Conditions Does Elafibranor Treat?
Elafibranor is being studied as a potential treatment for several liver-related conditions:
- Primary Biliary Cholangitis (PBC): This is a rare, long-term autoimmune disease of the liver. In PBC, the immune system mistakenly attacks the small bile ducts in the liver, leading to damage and scarring.
- Nonalcoholic Steatohepatitis (NASH): This is a type of fatty liver disease not caused by alcohol use. In NASH, fat buildup in the liver leads to inflammation and liver cell damage.
- Nonalcoholic Fatty Liver Disease (NAFLD): This is a broader term that includes NASH and refers to a range of liver conditions caused by excess fat in the liver not due to alcohol consumption.
How Does Elafibranor Work?
While the exact mechanism is still being studied, Elafibranor is believed to work by targeting certain receptors in the liver that play a role in metabolism and inflammation. By activating these receptors, Elafibranor may help to reduce liver inflammation, decrease fat accumulation in the liver, and improve the overall function of liver cells.
Clinical Trials and Research
Elafibranor is currently being studied in various clinical trials to assess its effectiveness and safety:
- Primary Biliary Cholangitis (PBC): Trials are evaluating how well Elafibranor can reduce levels of alkaline phosphatase (ALP), a marker of liver damage, in patients with PBC who haven't responded well to standard treatments.
- Nonalcoholic Steatohepatitis (NASH): Studies are looking at whether Elafibranor can improve liver health in patients with NASH, including reducing liver scarring (fibrosis) and resolving NASH symptoms.
- Nonalcoholic Fatty Liver Disease (NAFLD): Research is examining how Elafibranor affects the composition of fats in the liver of patients with NAFLD.
Dosage and Administration
In clinical trials, Elafibranor is typically given as an oral tablet, taken once daily. The most common doses being studied are 80 mg and 120 mg. However, it's important to note that as Elafibranor is still in the research phase, the optimal dosage may change based on ongoing study results.
Potential Side Effects
As with any medication, Elafibranor may cause side effects. The full range of potential side effects is still being studied in clinical trials. Researchers are closely monitoring for any adverse events, changes in laboratory test results, vital signs, and physical examinations. It's important to remember that not everyone experiences side effects, and the benefits of the medication may outweigh the risks for many patients.
Ongoing Research and Future Directions
Research on Elafibranor is ongoing, with several studies looking at its effects in different patient populations:
- Studies in elderly patients to understand how age affects the body's processing of the drug.
- Research in patients with liver impairment to determine if dosage adjustments are needed.
- Investigations in patients with kidney impairment to assess how the drug is processed in these individuals.
- Studies in children and adolescents with NASH to evaluate the drug's safety and effectiveness in younger populations.
These ongoing studies will help researchers better understand how Elafibranor works in different groups of patients and potentially expand its use to treat various liver conditions.